ABSTRACT
Breast conserving surgery with adequate surgical margins followed by radiotherapy has been shown to be oncologically equivalent to a mastectomy. [1] [2] [3] Despite this, breast conserving surgery in patients with larger tumours or tumours in unfavourable anatomical locations in the breast can lead to poor aesthetic and psychological outcomes 4, 5 following radiotherapy. Larger breasts are at risk of receiving non-homogenous radiation dosage and at an increased risk of postoperative 6 and long-term cosmetic 7 complications. These complications may delay or even preclude the initiation of adjuvant therapy and impact adversely on survival. 8 Therapeutic mammoplasty is the use of breast reduction techniques to perform breast cancer resection. Using oncoplastic techniques such as therapeutic mammoplasty can extend the role of breast conserving surgery in ptotic or large-breasted patients to facilitate wider resection margins, immediate symmetry and perhaps less radiation toxicity. This article presents the experience of therapeutic mammoplasty in large or ptotic-breasted patients in the management of early breast cancer in a district general hospital setting.
Methods
All patients who underwent therapeutic mammoplasty between 2007 and 2011 at a single district general hospital breast unit were included in the study. Patients were offered therapeutic mammoplasty if they had large breasts with grade 3 or 4 ptosis 9 with a tumour confined to a single quadrant, where the tumour volume was such that standard wide local excision would resect approximately 20% or more of their estimated breast volume (by clinical assessment alone). Patients who were current smokers, insulin
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Patient records were reviewed for demographic characteristics, co-morbidities, surgical technique, adjuvant treatment, postoperative complications and follow-up duration. Tumour size was based on pathological specimens rather than radiographic imaging. For those patients undergoing neoadjuvant therapy, tumour size was classified on the basis of initial pretreatment mammographic tumour size and not on tumour size at the time of surgery. In this series, patients with objective clinical and radiological response after neoadjuvant therapy were offered breast reduction if appropriate. Hormone receptor and HER2/neu status were also noted for each specimen.
Surgical technique
All patients received preoperative intravenous antibiotics (cefuroxime 1.5g) at induction of anaesthesia with two further postoperative intravenous doses. Standard breast reduction markings (Fig 1) were used preoperatively. This involved placement of the new nipple height at the level of the projected inframammary fold, dropping of perpendicular limbs to the meridian and maintaining the nipple viability via an inferior pedicle (Fig 2) . After skin incision, skin de-epitheliasation is performed. Skin flaps are then elevated, paying careful attention to leave an appropriate subcutaneous tissue plane to preserve the viability of the skin envelope. Local mobilisation of the breast off the chest wall is followed by formal wide local excision of the lesion along with standard resection of breast tissue. Oncological tissue is orientated and marked, and sent separately to normal breast tissue resected. Because the wide local excision defect is closed, surgical clips are placed to facilitate accurate radiotherapy planning.
On completion of oncological excision, resection of normal breast tissue, shaping of the breast mound and filling of the defect using mobilised parenchymal tissue is performed. An inferior pedicle breast reduction technique was used in the majority of cases, allowing for reshaping of the breast mound and closure of dead space by displacement and rotation of the dermoglandular pedicle, which has a minimum width of 8cm to preserve nipple areolar complex perfusion. The skin is then closed without tension in layers, creating an inverted T scar. The nipple is repositioned at the level of the inframammary fold and re-inset in its new location. The contralateral breast reduction is performed, adjusting for underlying asymmetry in volume of tissue resected to provide symmetry (Fig 3) .
Results
From January 2007 to December 2011, 20 patients undergoing therapeutic mammoplasty were identified and included in our review ( Table 1 ). The median follow-up duration was 36 months (interquartile range [IQR]: 10-45 months). The mean patient age at the time of reduction mammoplasty was 50 years. Nine patients (45%) had right-sided breast lesions and the remainder (55%) had left-sided breast lesions. The co-morbidities in our series included hypertension (n=5, 25%), hypercholesterolaemia (n=4, 20%), hypothyroidism (n=1, 5%) and type 2 diabetes mellitus (n=1, 5%) although the vast majority of our patients were healthy without significant medical issues. Five patients (25%) had a history of prior or ongoing smoking. The median body mass index was 28.5kg/m 2 (IQR: 26-33kg/m 2 ).
Breast cancer distribution
Pathology specimens and clinical data for the 20 cases were reviewed ( Table 1 ). The mean preoperative imaging lesion size was 35mm (range: 8-70mm). Pathological diagnoses of early breast cancer were seen in 17 cases. Invasive ductal carcinoma was the most common type (n=13), followed by invasive lobular carcinoma (n=4). Three cases received non-breast carcinoma diagnoses (phyllodes tumour, B-cell lymphoma and pseudoangiomatous stromal hyperplasia). These cases had concerning biopsy results for which the multidisciplinary team recommended excision.
Five patients with breast cancer had stage I disease (29%) and 12 patients had stage II disease (71%). The mean cancer size was 26mm (range: 8-39mm). The tumour size was 38mm for the phyllodes case. The B-cell lymphoma case had a tumour of 70mm and the fibroadenomatoid hyperplasia mass was 80mm.
Among the cancer cases, 16 were oestrogen receptor positive, 15 were progesterone receptor positive and there were no cases of HER2/neu positivity. Three patients had 
USING THERAPEUTIC MAMMOPLASTY TO EXTEND THE ROLE OF BREAST CONSERVING SURGERY IN WOMEN WITH LARGER OR PTOTIC BREASTS

CURRIE CHONG DAVIES
positive lymph nodes on preoperative testing or sentinel node dissection. All of these subsequently underwent completion axillary node dissection. There were no episodes of recurrence at the most recent follow-up visit.
Adjuvant therapy
In our cohort, all breast cancer patients were treated with adjuvant radiotherapy. Five patients received chemotherapy, four of whom received therapy in the neoadjuvant setting. All patients with hormone receptor positive invasive cancer (16/17) received adjuvant endocrine therapy.
Outcomes
Breast conservation with clear initial margins was successful in 16 of the 17 malignant cases. One patient underwent a completion mastectomy following positive margins with subsequent adjuvant chemotherapy.
There were no major postoperative complications, defined as requiring inpatient hospitalisation or an unplanned return to the operating theatre. There were four cases of minor complications including one wound infection requiring oral antibiotics alone and three cases of delayed wound healing at the T-junction. All of these were treated conservatively in the outpatient setting.
Discussion
This series demonstrates that therapeutic mammoplasty is a valuable alternative surgical option for early breast cancer in patients with large tumours and ptotic breasts to avoid poor outcomes from breast conserving surgery and, in some cases, to avoid mastectomy. Low rates of minor complications and the absence of major complications in this series mean this is a suitable approach in selected cases. Therapeutic mammoplasty is a technique developed from cosmetic breast reduction surgery. In high volume centres it has shown improved cosmetic results, and similar five-year survival and local recurrence rates to breast conserving surgery. [10] [11] [12] In our study, reduction mammoplasty was associated with a low rate of postoperative complications, which compares favourably with complication rates seen in other studies. 13, 14 Trials that evaluate wound complications of therapeutic mammoplasty for breast cancer have a relatively small number of cases. A systematic review from 2012 examining 1,702 patients in 25 cases series worldwide found wide ranging complication rates from 10% to 91%. 13 However, the vast majority of these were minor and adjuvant therapy was delayed in only 6% of patients. Although our study population was relatively healthy with few co-morbidities, a quarter of the patients had a history of prior or ongoing tobacco use, which did not seem to be a significant risk factor for the development of complications. All the major complications occurred in the early postoperative period, prior to the start of adjuvant radiation therapy. Although all of the patients received adjuvant radiation therapy, no later postoperative complications during or after radiation therapy were seen.
This finding is particularly compelling when considering therapeutic mammoplasty as an alternative to other breast conserving surgery such as wide local excision in women with larger breasts who will require adjuvant radiotherapy. Radiation dose homogeneity is far more difficult to achieve in large breasts. 15 It is common to have areas in the breast that receive 10-15% more dose and radiation fibrosis, chronic pain and poor cosmesis often result. 16 Therapeutic mammoplasty offers a way to achieve robust wide local excision margins and facilitate smaller, symmetrical breasts that more easily tolerate radiation.
In the literature, the most common complications were minor wound infections and haematoma formation, followed by delayed wound healing and minor wound dehiscence. 13 The rate of nipple-areola complex necrosis was 1-2%. Wound dehiscence occurs most frequently at the T-junction areas (Fig 1) . Closure of skin under tension or poor attention to skin envelope viability risks delayed wound healing, particularly in the T-junction. All the minor delayed wound healing seen in this series occurred in this T-junction area. Smoking did not appear to be a factor in complications in our series. Conversely, in the series reported by Munhoz et al, smoking was associated with a significantly increased risk of developing surgical complications following therapeutic mammoplasty. 17 Additionally, Munhoz et al demonstrated a significant increase in complications in obese patients. However, other studies have not seen that association. 18 Quality of life and patient satisfaction have been shown to be improved significantly by the use of therapeutic mammoplasty in managing early breast cancer. 19 Data from 2010 have demonstrated that the use of reduction mammoplasty techniques for reconstruction of partial mastectomy defects improves patient self-esteem and mental health when compared with patients undergoing breast conserving surgery without reconstruction. 20 Nevertheless, this study is limited by the use of non-validated quality of life assessment tools.
Conclusions
Therapeutic mammoplasty can provide an effective, oncologically safe operation in the district general hospital setting with limited complications while also achieving good aesthetic outcomes. It should therefore be considered as a surgical approach in early breast cancer for women with larger tumours and ptotic breasts.
